


Amendments to the claims

The following listing of claims replaces all prior listings.

1. (Currently amended) A cell adhesion inhibitory compound of formula (I): or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein:



X is $-\text{CO}_2\text{H}$;

Y is selected from the group consisting of $-\text{CO}-$, $-\text{CH}_2-$, $-\text{SO}_2-$ and $-\text{PO}_2-$;

R_1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl-substituted alkyl, cycloalkenyl-substituted cycloalkyl, alkoxy, alkenoxy, alkynoxy, alkylamino, alkenylamino, alkynylamino, N-alkylurea-substituted alkyl, alkylcarbonylamino-substituted alkyl, and aminocarbonyl-substituted alkyl;

[[R_3]] R_2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl;

[[R_4]] R_3 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, hydroxy-substituted alkyl, alkoxy-substituted alkyl, amino-substituted alkyl, thiol-substituted alkyl, alkylsulfonyl-substituted alkyl, (hydroxy-substituted alkylthio)-substituted alkyl, thioalkoxy-substituted alkyl, acylamino-substituted alkyl, alkylsulfonylamino-substituted alkyl, [N-(alkyl, alkenyl or alkynyl)-or N,N-[dialkyl, dialkenyl, dialkynyl or (alkyl, alkenyl)-amino]carbonyl-substituted alkyl, carboxyl-substituted alkyl, dialkylamino-substituted acylaminoalkyl, and [[and]] amino acid side chains selected from arginine, asparagine, glutamine, S-methyl cysteine, methionine and corresponding sulfoxide and sulfone derivatives

thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, norleucine, alanine, ornithine, glutamine, valine, threonine, serine, aspartic acid, beta-cyanoalanine, and allothreonine;

R₄ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, amido, aminocarbonyl, mono- or dialkylaminocarbonyl, mono- or diacylaminocarbonyl, aliphatic acyl, alkyl optionally substituted with substituents selected from the group consisting of amino, carboxy, hydroxy, mercapto, mono- or dialkylamino, mono- or diacylamino, alkoxy, alkenoxy, thioalkoxy, thioalkenoxy, and thioalkynoxy; and n is 0, 1 or 2.

2. (original) The compound according to claim 1, wherein R₄ is selected from the group consisting of alkyl, cycloalkyl, alkyenyl, cycloalkenyl, and alkynyl.

3. (withdrawn) The compound according to claim 1, wherein R₁ is selected from the group consisting of cyanomethyl, cyclohexylmethyl, methyl, n-hexyl, t-butoxy, t-butylamino, 5-(N'-t-butylurea)pentyl, 2,2-dimethylpropyl, and hydroxyethylthiomethyl.

4. (withdrawn) The compound according to claim 1, wherein R₁ is selected from the group consisting of cyanomethyl, cyclohexylmethyl, methyl, n-hexyl, t-butoxy, t-butylamino, 5-(N'-t-butylurea)pentyl, and 2,2-dimethylpropyl.

5. (original) The compound according to claim 1, wherein R₂ is hydrogen or methyl.

6. (original) The compound according to claim 5, wherein R₂ is hydrogen.

7. (original) The compound according to claim 1, wherein R₃ is selected from the group consisting of 2-(methylsulfonyl)-ethyl, 3-(hydroxy-propylthio)-methyl, 4-(methylsulfonylamino)-butyl, 4-acetylaminoethyl, aminomethyl, butyl, hydroxymethyl, isobutyl, methyl, methylthiomethyl, propyl, N,N-(methylpropargyl)-amino, 2-(methylthio)-ethyl, 2-(N,N-dimethylamino)-ethyl, 4-amino-butyl, t-butoxy-carbonylaminoethyl, sec-butyl, t-butyl, N,N-dimethyl-aminocarbonylmethyl, 1,1-ethano, 1-hydroxyethyl, 1-methoxyethyl, carbonylmethyl, 2-methylsulfinylethyl, asparagine side-chain, 4-(methylurea)butyl, 4-methylsulfonylaminoethyl,

hydroxymethylthiomethyl, 2-methylsulfonyl-ethyl, 4-propionylaminobutyl, 4-ethoxycarbonylaminobutyl, methoxycarbonylaminobutyl, carbomethoxymethylthiomethyl, 4-*t*-butylureabutyl, carboxymethylthiomethyl, dimethylamidomethylthiomethyl, acetylaminopropyl, 3-methylureapropyl, 4-trifluoroacetylaminobutyl, dimethylaminomethylthiomethyl, dimethylaminoethylthiomethyl, and 4-(dimethylaminoacetyl-amino)butyl.

8. (original) The compound according to claim 7, wherein R_3 is selected from the group consisting of 2-(methylsulfonyl)-ethyl, 3-(hydroxypropylthio)-methyl, 4-(methylsulfonylamino)-butyl, 4-acetylaminobutyl, aminomethyl, butyl, hydroxymethyl, isobutyl, methyl, methylthiomethyl, propyl, *N,N*-(methylpropargyl)-amino, 2-(methylthio)-ethyl, 2-(*N,N*-dimethylamino)-ethyl, 4-amino-butyl, *t*-butoxy-carbonylaminomethyl, *sec*-butyl, *t*-butyl, *N,N*-dimethyl-aminocarbonylmethyl, 1,1-ethano, 1-hydroxyethyl, 1-methoxyethyl, carbonylmethyl, 2-methylsulfinylethyl, and asparagine side chain.

9. (original) The compound according to claim 7, wherein R_3 is selected from the group consisting of 2-(methylsulfonyl)-ethyl, 3-(hydroxypropylthio)-methyl, 4-(methylsulfonylamino)-butyl, 4-acetylaminobutyl, isobutyl, 2-(methylthio)-ethyl, and 4-(ethoxycarbonylamino)butyl.

10. (original) The compound according to claim 9, wherein R_3 is selected from the group consisting of 2-(methylsulfonyl)-ethyl, 3-(hydroxypropylthio)-methyl, 4-(methylsulfonylamino)-butyl, 4-acetylaminobutyl, isobutyl, and 2-(methylthio)-ethyl.

11. (withdrawn) The compound according to claim 1, wherein R_4 is selected from the group consisting of methyl, 4-methylsulfonylamino, 4-propionylamino, *n*-pentyl, carboxymethyl, 2-carboxyethyl, allyl, ethynyl, 2-propenyl, 2-propynyl, and propyl.

12. (withdrawn) The compound according to claim 11, wherein R_4 is methyl.

13. (withdrawn) The compound according to claim 11, wherein R_4 is allyl or ethynyl.

14. (original) The compound according to claim 1, wherein Y is -CO-, -CH₂- or -SO₂-.

15. (original) The cell adhesion inhibitory compound according to claim 14, wherein Y is -CO-.

16. (original) The cell adhesion inhibitory compound according to claim 1, wherein n is 1.

17. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1 in an amount effective for ~~prevention, inhibition~~ or suppression of VLA-4 mediated cell adhesion and a pharmaceutically acceptable carrier.

18. (original) The pharmaceutical composition according to claim 17, further comprising an agent selected from the group consisting of corticosteroids, bronchodilators, antiasthmatics, antiinflammatories, antirheumatics, immunosuppressants, antimetabolites, immunomodulators, antipsoriatics and antidiabetics.

19. (Currently amended) A method of ~~preventing, inhibiting or~~ suppressing VLA-4 mediated cell adhesion in a mammal comprising the step of administering to said mammal the pharmaceutical composition according to claim 17.

20. (Currently amended) The method according to claim 19, wherein said method is used for ~~preventing, inhibiting or~~ suppressing cell adhesion-associated inflammation.

21. (Currently amended) The method according to claim 20, wherein said method is used for ~~preventing, inhibiting or~~ suppressing cell adhesion-associated immune or autoimmune response.

Applicant : Steven P. Adams et al.
Serial No. : 10/679,478
Filed : October 7, 2003
Page : 6 of 9

Attorney's Docket No.: 14937.0003 C2

22. (Currently amended) The method according to claim 19, wherein said method is used to treat ~~or prevent~~ a disease selected from the group consisting of asthma, arthritis, psoriasis, transplantation rejection, multiple sclerosis, diabetes and inflammatory bowel disease.